MiniHRS kit (Mini Homologous Recombination)

The MiniHRS panel (mini Homologous Recombination Solution) covers the coding regions and the splicing junctions (± 25 bp min) of 4 genes, associated, among others, with breast and ovarian cancer: BRCA1, BRCA2, RAD51C y TP53.

In addition, it allows the detection of SNVs and Indels as well as ALU inserts.

The kit uses NGS capture technology and is intended for use on Illumina platforms. The results are interpreted in the SOPHiA DDM platform, designed for the analysis and protection of NGS clinical data in routine diagnosis.

kit SOPHiA DDM3

SOPHiA DDM also integrates OncoPortal, a tool that contains relevant somatic classifications, based on variant-drug-disease association, best available treatments and relevant clinical trials.

In addition to MiniHRS kit, we have other panels for clinical diagnosis in areas such as metabolism, oncohematology, nephrology or cardiology.

  • Sophia panel cancer hereditario NGS carrusel 1
  • sophia carrusel
  • Sophia panel cancer hereditario NGS carrusel 2
  • Sophia panel cancer hereditario NGS carrusel 3

Area:

Reproductive System, Solid tumor, Tumor Types

Documents:

Consult our experts

Google reCaptcha: Invalid site key.

Related products

SureSelect Cancer CGP Assay

Targeted-enrichment NGS pan-cancer panel for comprehensive genomic profiling (CGP) of solid tumours. Designed to detect somatic variants at DNA level (SNVs, indels, CNVs, translocations) and RNA level (gene fusions), as well as to assess complex immuno-oncology biomarkers such as tumour mutational burden (TMB), microsatellite instability (MSI) and homologous recombination deficiency (HRD). Detailed Description Operating principle…
Agilent
Next Generation Sequencing (NGS)

SeqOne HRD Solution con Agilent SureSelect CD HRR17 Panel

HRD analysis solution combining low-coverage whole-genome sequencing (shallow/low-pass WGS) and a targeted gene panel to detect genomic instability, BRCA1/2 alterations and other genes related to homologous recombination. It is designed for laboratories wishing to implement HRD testing in-house with an automated, efficient and clinically validated workflow. Detailed Description SeqOne’s HRD solution combines shallow WGS and…
Agilent
Next Generation Sequencing (NGS)

OncoSELECT®

Comprehensive targeted liquid biopsy assay designed to support decision-making in oncology through the analysis of 74 clinically relevant genes. The solution encompasses everything from library preparation reagents to bioinformatics analysis, clinical interpretation and the generation of detailed reports. 3.- Detailed Description Operating principle OncoSELECT® is an advanced liquid biopsy panel based on circulating cell-free DNA…
OncoDNA
Next Generation Sequencing (NGS)

MSK-ACCESS® powered with SOPHiA DDM™

In-house liquid biopsy solution based on hybrid-capture next-generation sequencing (NGS) technology for the ultrasensitive detection of somatic alterations in circulating cell-free DNA from plasma. Developed in collaboration with Memorial Sloan Kettering Cancer Center (MSK), it implements a robust matched tumor-normal sequencing approach (plasma cfDNA + white blood cell DNA) to filter germline variants and mutations…
SOPHIA Genetics
Next Generation Sequencing (NGS)